The FAK inhibitor APG-2449, with an IC50 value of 5.4 nM, demonstrated effective and sustained antitumor activity in NSCLC models when administered either alone or in combination with AZD-9291 and trametinib. Here, PTK2 is linked to non-small cell lung carcinoma.